Relative Efficacy of Next-Generation Incretin Therapies for Cardio-Renal Protection in Type 2 Diabetes: Evidence From a Network Meta-Analysis - PubMed
2 days ago
- #GLP-1 receptor agonists
- #cardiovascular outcomes
- #renal outcomes
- Study compares cardiovascular and renal effects of modern GLP-1RAs and dual agonists in high-risk T2D populations.
- Semaglutide showed the most consistent reduction in MACE and MI versus placebo.
- Dulaglutide 1.5 mg and tirzepatide 15 mg significantly reduced stroke risk.
- Renal effects varied by endpoint, with UACR showing marked reductions, particularly with dulaglutide plus dapagliflozin.
- PCA confirmed strong cardiometabolic-renal interdependence.
- Further long-term head-to-head trials are needed to confirm findings.